This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.
From the blog
Imerys Talc America and Cyprus Mines Corporation are Creating a Trust for Asbestos Victims
Imerys Talc America and its former owner, Cyprus Mines Corporation, will create a collective $862 million trust. The reason for the trust is to settle personal injury claims that allege the company’s asbestos contaminated talc caused people’s cancer. This is after both groups filed reorganization plans and disclosure statements on[…]
Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration (PITHAC)
Within the context of pleural carcinosis, the present study is a dose escalation with determination of the maximum tolerated doses (MTD) of pressurized cisplatin administration associated to moderate hyperthermia in the pleura. This will be followed by an expansion phase at the recommended dose (RD).
ADI-PEG20 Improves Survival in Mesothelioma Patients
ADI-PEG20 is showing promising results for mesothelioma. It is the first treatment to be fully incorporated with chemotherapy in 20 years. The drug will bring hope to thousands of mesothelioma survivors and their families. The drug works by blocking a cancer’s food supply, preventing the spread of the cancer. It[…]
Asbestos and Other Carcinogens Were in U.S. Missile Silos
The U.S. Air Force is investigating asbestos and other carcinogens at nuclear missile bases. According to the Associated Press, the use of these carcinogens dates back to the 1980s. There are reports showing that the Air Force knew about the toxic chemicals being used at nuclear launch silos for decades.[…]
Galinpepimut-S Alongside Opdivo Improves Survival in Mesothelioma Patients
Sellas Life Sciences recently reported results from its Phase I clinical trial showing that survival was improved in pleural mesothelioma patients due to its treatment. The trial looked at the treatment called galinpepimut-S (GPS), an immunotherapy vaccine. There were 10 patients in the study with relapsed or refractory mesothelioma. Nine[…]
Breath Test Could Improve Diagnosis of Mesothelioma
A new way to diagnose mesothelioma may have been discovered. Researchers have found that the exhaled breath of patients could have the potential to be a screening tool for malignant pleural mesothelioma. The information was presented at the International Association for the Study of Lung Cancer 2023 World Conference on[…]
Occupational and Environmental Exposure to Asbestos Reduces Longevity in Patients
Mesothelioma is a hard cancer to treat that is mainly caused by asbestos. People with this cancer typically do not live very long after diagnosis, but some people live longer than expected. A study recently published in the journal Toxics looked at people with mesothelioma and asbestos-caused lung cancer. All[…]
Altered CAR-T Cell Therapy for the Treatment of Mesothelioma
Immunotherapy is an innovative and groundbreaking way to treat cancer. It uses the immune system to fight and kill cancer cells. One immunotherapy treatment that is showing good results for certain cancers is called CAR-T cell therapy, which is able to target specific proteins on cancer cells. One of the[…]
Radiation and Immunotherapy Combination Improves Survival in Lung Cancer Patients
A new study looking at low dose radiation and immunotherapy is showing promising results for non-small cell lung cancer. Patients treated with the combination had higher progression free survival compared to patients who received immunotherapy alone. Research was completed at Weill Cornell Medicine, NewYork-Presbyterian as well as at Columbia University[…]
Skip to content